A simple method of hiPSCs differentiation into insulin-producing cells is improved with vitamin C and RepSox.

PLoS One

Department of Life Sciences (Biology), Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan.

Published: November 2021

Human induced pluripotent stem cells (hiPSCs) are considered a promising source of pancreatic β-cells for the treatment of diabetes. However, this approach is limited by issues such as low efficiency and high cost. Here, we have developed a new protocol to induce insulin-producing cells. To reduce costs, we decreased the number of reagents and replaced protein reagents with chemical compounds. In this method, we increased induction efficiency with ascorbic acid (vitamin C) and an ALK5 inhibitor, RepSox. In 2D culture, the majority of cells were immature β-cells with low glucose-stimulated insulin secretion. Transferring to 3D culture immediately after endocrine progenitor cell differentiation, however, improved glucose-stimulated insulin secretion. This simplified method will contribute to realizing transplantation therapy of β-cells using iPSCs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274930PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0254373PLOS

Publication Analysis

Top Keywords

insulin-producing cells
8
glucose-stimulated insulin
8
insulin secretion
8
simple method
4
method hipscs
4
hipscs differentiation
4
differentiation insulin-producing
4
cells
4
cells improved
4
improved vitamin
4

Similar Publications

Type 1 diabetes mellitus is an autoimmune condition characterized by the destruction of pancreatic β-cells, necessitating insulin therapy to prevent life-threatening complications such as diabetic ketoacidosis. Despite advancements in glucose monitoring and pharmacological treatments, managing this disease remains challenging, often leading to long-term complications and psychological burdens, including diabetes distress. Advanced treatment options, such as whole-pancreas transplantation and islet transplantation, aim to restore insulin production and improve glucose control in selected patients with diabetes.

View Article and Find Full Text PDF

Biotechnology Revolution Shaping the Future of Diabetes Management.

Biomolecules

December 2024

Discipline of Microbiology, Department XIV Microbiology, University of Medicine and Pharmacy from Timisoara, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania.

Diabetes mellitus (DM) has a millennia-long history, with early references dating back to ancient Egypt and India. However, it was not until the 20th century that the connection between diabetes and insulin was fully understood. The sequencing of insulin in the 1950s initiated the convergence of biotechnology and diabetes management, leading to the development of recombinant human insulin in 1982.

View Article and Find Full Text PDF

ISG15 increases the apoptosis of β cells in type 1 diabetes.

Cell Signal

January 2025

Department of Endocrinology, The Third Xiangya Hospital, Central South University, 410007 Changsha, Hunan, China. Electronic address:

Type 1 diabetes (T1D) is an autoimmune disease characterized by hyperglycemia caused by the destruction of insulin-producing β cells. Viral infection is an important environmental factor which is associated with the islet autoimmunity in genetically susceptible individuals. Loss of β-cells and triggering of insulitis following viral infection could result from several non-exclusive mechanisms.

View Article and Find Full Text PDF

Type 1 Diabetes Mellitus (T1D) is an autoimmune disease caused by unremitting immune attack on pancreas insulin-producing beta cells. Persistence of the autoimmune response is mediated by TCF1+ Ly108+ progenitor CD8+ T (T ) cells, a stem-like population that gives rise to exhausted effectors with limited cytolytic function in chronic virus infection and cancer. What paradoxically drives T conversion to highly cytolytic effectors in T1D, however, remains unclear.

View Article and Find Full Text PDF

Pathophysiological characterization of the ApoE mouse: A model of diabetes and atherosclerosis.

Methods

January 2025

Translational Research On Renal and Cardiovascular Diseases (TRECARD), Department of Physiology and Pharmacology, University of Salamanca, 37007 Salamanca, Spain; Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain. Electronic address:

The high prevalence of type 2 diabetes and atherosclerosis makes essential the availability of in vivo experimental models that accurately replicate the pathophysiological mechanisms of these diseases. Apolipoprotein E knockout mice (ApoE) have been used in atherosclerosis studies, and the db/db mice show hyperphagia and obesity. Mice harbouring both alterations (i.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!